[go: up one dir, main page]

CA2116107A1 - Administration de poly-ou d'oligonucleotides ciblee sur des cellules - Google Patents

Administration de poly-ou d'oligonucleotides ciblee sur des cellules

Info

Publication number
CA2116107A1
CA2116107A1 CA002116107A CA2116107A CA2116107A1 CA 2116107 A1 CA2116107 A1 CA 2116107A1 CA 002116107 A CA002116107 A CA 002116107A CA 2116107 A CA2116107 A CA 2116107A CA 2116107 A1 CA2116107 A1 CA 2116107A1
Authority
CA
Canada
Prior art keywords
cell
molecular complex
oligonucleotide
antisense
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002116107A
Other languages
English (en)
Inventor
George Y. Wu
Catherine H. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2116107A1 publication Critical patent/CA2116107A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002116107A 1991-09-05 1992-09-04 Administration de poly-ou d'oligonucleotides ciblee sur des cellules Abandoned CA2116107A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75508391A 1991-09-05 1991-09-05
US755,083 1991-09-05
US78811991A 1991-11-04 1991-11-04
US788,119 1991-11-04
US86400392A 1992-04-03 1992-04-03
US864,003 1992-04-03

Publications (1)

Publication Number Publication Date
CA2116107A1 true CA2116107A1 (fr) 1993-03-18

Family

ID=27419474

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002116107A Abandoned CA2116107A1 (fr) 1991-09-05 1992-09-04 Administration de poly-ou d'oligonucleotides ciblee sur des cellules

Country Status (6)

Country Link
EP (1) EP0666923A1 (fr)
JP (1) JPH07500820A (fr)
KR (1) KR100252547B1 (fr)
AU (1) AU681997B2 (fr)
CA (1) CA2116107A1 (fr)
WO (1) WO1993004701A1 (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
AU4528493A (en) * 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
WO1994011494A1 (fr) * 1992-11-09 1994-05-26 Thomas Jefferson University Oligonucleotides antisens utilises pour inhiber l'expression de genes de collagene ayant subis une mutation et de type sauvage
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
ATE312188T1 (de) * 1993-01-22 2005-12-15 Univ Research Corp Lokalisierung von therapeutischen mitteln
EP0693130A1 (fr) * 1993-04-05 1996-01-24 The University Of Connecticut Apport cible de genes codant des polyribonucleotides antisens
EP0693939A1 (fr) * 1993-04-14 1996-01-31 Roche Diagnostics GmbH Peptides de tranfert d'acides nucleiques et leur utilisation pour injecter des acides nucleiques dans des cellules eucaryotes
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE4331012A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
DE4331011A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
JPH10501681A (ja) * 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
EP0759087B1 (fr) * 1994-05-13 2001-03-28 Chiron Corporation Compositions et procedes de criblage de vecteurs d'apport de genes
FR2721612B1 (fr) * 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
DE4427980A1 (de) * 1994-08-08 1996-02-15 Bayer Ag Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
WO1996024378A2 (fr) 1995-02-10 1996-08-15 Worcester Foundation For Biomedical Research, Inc. Apport de composes exogenes
AU5122796A (en) * 1995-03-31 1996-10-16 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
ATE466948T1 (de) 1997-03-11 2010-05-15 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
DE69818987T2 (de) 1997-05-21 2004-07-29 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
AU7727298A (en) * 1997-06-06 1998-12-21 Regents Of The University Of Michigan, The Neuregulin response element and uses therefor
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
WO1999016883A2 (fr) 1997-10-01 1999-04-08 Dana-Farber Cancer Institute Stabilisation des glycoproteines trimeres d'enveloppe au moyen de liaisons bisulfure introduites dans un ectodomaine de la glycoproteine gp41
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
DK1053355T3 (da) 1998-02-11 2002-02-11 Pe Corp Ny PNA- og DNA-konjugater og metoder til fremstilling heraf
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
DE19858005B4 (de) * 1998-12-16 2007-02-08 november Aktiengesellschaft, Gesellschaft für Molekulare Medizin Synthetisches Nucleinsäure-Partikel
EP1210121A2 (fr) 1999-08-24 2002-06-05 Cellgate Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
ES2238799T3 (es) * 1999-09-09 2005-09-01 Curevac Gmbh Transferencia de arn-m.
AU2000240366B2 (en) * 2000-03-28 2005-08-04 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
EP1286699A2 (fr) * 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Composition pour l'introduction de composes dans des cellules
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
AU2002255995A1 (en) 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
EP2351583A1 (fr) 2002-11-26 2011-08-03 Facet Biotech Corporation Anticorps chimériques et humanisés pour intégrine alpha5 béta1 permettant de moduler l'angiogénèse
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
EP1697399B1 (fr) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
WO2006081331A2 (fr) 2005-01-25 2006-08-03 Prolexys Pharmaceuticals, Inc. Erastine et proteines de liaison d'erastine, et utilisations de celles-ci
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
EP2111553B1 (fr) 2007-01-24 2018-09-19 Carnegie Mellon University Biocapteurs optiques
US20110038935A1 (en) 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
CA2752854A1 (fr) 2009-02-18 2010-08-26 Carnegie Mellon University Colorants dendrimeres desactives pour detection de brillant
CA2759848C (fr) 2009-05-05 2018-12-04 Novimmune S.A. Anticorps anti-il-17f et leurs methodes d'utilisation
EP3252068A3 (fr) 2009-10-12 2018-03-14 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
US9597346B2 (en) 2010-01-15 2017-03-21 Cornell University Methods for reducing protein levels in a cell
EP2526205A1 (fr) 2010-01-21 2012-11-28 Dana-Farber Cancer Institute, Inc. Plate-forme de criblage génétique spécifique du contexte pour assister la découverte de gènes et la validation de cibles
WO2011150079A1 (fr) 2010-05-25 2011-12-01 Carnegie Mellon University Sondes ciblées de physiologie cellulaire
EP3327039B1 (fr) 2010-06-02 2021-08-11 Dana Farber Cancer Institute, Inc. Anticorps monoclonaux humanisés et méthodes d'utilisation
JP6228010B2 (ja) 2010-12-27 2017-11-08 ブラウン ユニバーシティ ビグリカンおよびユートロフィンに関する治療法および診断法
US9453076B2 (en) 2012-03-29 2016-09-27 Novimmune S.A. Anti-TLR4 antibodies and uses thereof
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
MX370848B (es) 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
ES2784631T3 (es) 2012-12-03 2020-09-29 Novimmune Sa Anticuerpos anti-CD47 y métodos de uso de los mismos
AU2015231164B2 (en) 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015164865A1 (fr) 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Anticorps neutralisant le coronavirus du syndrome respiratoire du moyen-orient et procédés d'utilisation de ceux-ci
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
KR20170081699A (ko) 2014-11-18 2017-07-12 얀센 파마슈티카 엔.브이. Cd47 항체, 방법 및 용도
JP7033082B2 (ja) 2016-02-05 2022-03-09 ナノビュー バイオサイエンシズ インコーポレイテッド 表面マーカーを有するエキソソームの検出
CN109310885B (zh) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b靶向抗体-药物缀合物及其使用方法
CN109689689B (zh) 2016-07-22 2022-12-06 丹娜法伯癌症研究所公司 糖皮质激素诱导肿瘤坏死因子受体(gitr)抗体及其使用方法
WO2018045379A1 (fr) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition et méthodes de traitement des déreglements des lymphocytes b
BR112019004214A2 (pt) 2016-09-06 2019-05-28 Dana Farber Cancer Inst Inc métodos para tratar ou prevenir infecção pelo vírus zika
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
CN112334484A (zh) 2018-03-14 2021-02-05 诺维莫尼公司 抗-CD3ε抗体及其应用方法

Also Published As

Publication number Publication date
KR100252547B1 (ko) 2000-09-01
JPH07500820A (ja) 1995-01-26
AU2678092A (en) 1993-04-05
AU681997B2 (en) 1997-09-18
WO1993004701A1 (fr) 1993-03-18
EP0666923A4 (fr) 1995-01-20
EP0666923A1 (fr) 1995-08-16

Similar Documents

Publication Publication Date Title
CA2116107A1 (fr) Administration de poly-ou d'oligonucleotides ciblee sur des cellules
US6030954A (en) Targeted delivery of poly- or oligonucleotides to cells
JP6584888B2 (ja) 組織特異的ペプチドコンジュゲートおよび方法
CA2210353C (fr) Sequences guides externes stabilisees
EP0894129B1 (fr) Sequence guides externes courtes
US20070155686A1 (en) RNAi modulation of HIF-1 and therapeutic uses thereof
Cheng et al. Gene modulation for treating liver fibrosis
US5843770A (en) Antisense constructs directed against viral post-transcriptional regulatory sequences
HU215187B (hu) Eljárás az RNS funkcióját gátló genetikai egységek előállítására, és eljárás sejtekbe való bevitelükre
JPH09511382A (ja) 抗ｂ型肝炎性ポリ及びオリゴヌクレオチド
US20230383294A1 (en) Novel rna compositions and methods for inhibiting angptl3
CN115176011A (zh) 用于抑制pcsk9的组合物和方法
US20030166512A1 (en) Protein carrier system for therapeutic oligonucleotides
US20220025367A1 (en) Novel rna compositions and methods for inhibiting angptl8
CA2105595A1 (fr) Polynucleotides antisens
Bachmann et al. Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides
US20040072783A1 (en) Nucleozymes with endonuclease activity
Carmichael et al. Targeted delivery of anti-hepatitis B antisense oligonucleotides
AU6497894A (en) Targeted delivery of genes encoding antisense polyribonucleotides
Elhamess et al. Antitumor vectorized oligonucleotides in a model of ewing sarcoma: unexpected role of nanoparticles
WO1997014440A1 (fr) Conjugaison d'oligonucleotides anti-sens c-myc avec le cholesterol pour renforcer de maniere importante leur effet inhibiteur sur l'hyperplasie de la neo-intima
AU2017202166B2 (en) Tissue specific peptide conjugates and methods
CN117247940A (zh) 用于减少PD-L1表达的siRNA、缀合物及药物组合物
WO2023116607A9 (fr) Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation associés
TW202449154A (zh) 抑制lpa之基因表現之組合物及方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead